Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Elacestrant
Drug: Ribociclib
Drug: Everolimus
Drug: Alpelisib
Drug: Capivasertib
Drug: Palbociclib
Drug: Abemaciclib

First Posted Date: 2022-10-03

Last Posted Date: 2024-11-18

Lead Sponsor: Stemline Therapeutics, Inc.

Target Recruit Count: 400

Registration Number: NCT05563220

Locations: 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸
Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States

and more 108 locations

Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer
ER-positive Breast Cancer
HER2-negative Breast Cancer
Breast Cancer

Interventions: Drug: OP-1250
Drug: Ribociclib
Drug: Alpelisib
Drug: Everolimus

First Posted Date: 2022-08-19

Last Posted Date: 2024-10-03

Lead Sponsor: Olema Pharmaceuticals, Inc.

Target Recruit Count: 155

Registration Number: NCT05508906

Locations: 🇺🇸
Advent Health Hematology and Oncology, Orlando, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 13 locations

Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Phase 3

Recruiting

Conditions: GEP-NET
Pancreatic NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid Tumor
Carcinoid

Interventions: Drug: RYZ101
Drug: Everolimus
Drug: Sunitinib
Drug: Octreotide
Drug: Lanreotide

First Posted Date: 2022-07-28

Last Posted Date: 2024-11-13

Lead Sponsor: RayzeBio, Inc.

Target Recruit Count: 288

Registration Number: NCT05477576

Locations: 🇪🇸
Research Facility, Zaragoza, Spain

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Phase 3

Recruiting

Conditions: Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Drug: ONC201
Drug: Everolimus
Radiation: Radiotherapy

First Posted Date: 2022-07-27

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 409

Registration Number: NCT05476939

Locations: 🇩🇰
Aarhus Universitetshospital Skejby, Aarhus, Denmark
🇪🇸
Hospital Vall D´Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario y Politécnico de La Fe, Valence, Spain

and more 39 locations

Pilot Trial for Treatment of Recurrent Glioblastoma

Early Phase 1

Recruiting

Conditions: Recurrent Glioblastoma
Glioblastoma
Recurrent Disease

Interventions: Drug: Afatinib
Drug: Dasatinib
Drug: Palbociclib
Drug: Everolimus
Drug: Olaparib

First Posted Date: 2022-06-27

Last Posted Date: 2024-06-03

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 10

Registration Number: NCT05432518

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3

Conditions: HER2+ Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pyrotinib
Drug: Anti-PD-1 monoclonal antibody
Drug: CDK4/6 inhibitor
Drug: Pertuzumab
Drug: Capecitabine
Drug: Nab paclitaxel
Drug: AI
Drug: T-DM1
Drug: Everolimus

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 120

Registration Number: NCT05429684

Locations: 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
Jin Yang, Xi'an, Shaanxi, China

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3

Active, not recruiting

Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Giredestrant
Drug: Exemestane
Drug: Fulvestrant
Drug: Everolimus
Drug: LHRH Agonist
Drug: Tamoxifen
Drug: Dexamethasone Mouth Rinse

First Posted Date: 2022-04-01

Last Posted Date: 2024-10-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 320

Registration Number: NCT05306340

Locations: 🇺🇸
Alabama Oncology - Bruno Cancer Center, Birmingham, Alabama, United States
🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸
The Dignity Health Cancer Institute, Phoenix, Arizona, United States

and more 203 locations